Aravive Inc (DELISTED) (ARAV:DL)
0.0401
0.00 (0.00%)
USD |
NASDAQ |
Feb 07, 16:00
Price Chart
Key Stats
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials. |
URL | https://www.aravive.com |
Investor Relations URL | http://ir.versartis.com/ |
HQ State/Province | Texas |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 15, 2024 (est.) |
Last Earnings Release | Aug. 21, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials. |
URL | https://www.aravive.com |
Investor Relations URL | http://ir.versartis.com/ |
HQ State/Province | Texas |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 15, 2024 (est.) |
Last Earnings Release | Aug. 21, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |